Sam Brusco, Associate Editor09.08.22
Centinel Spine has completed the first implantation of its prodisc C Vivo cervical total disc replacement (TDR). The first procedure was performed in Dallas-Fort Worth by orthopedic spine surgeon Jason Tinley, MD, founder of DFW Center for Spinal Disorders.
"This patient had severe left-sided neck pain radiating into the forearm and thumb and a left C5/6 disc herniation," Dr. Tinley told the press. "Having the intraoperative options of a convex dome with spikes (prodisc C Vivo) versus a flat endplate component with keel (prodisc C) gave me the modularity to maximize endplate contact and stability, thus decreasing bone removal, risk of heterotopic ossification, subsidence, or implant failure. Ultimately, this allows me to best restore motion while also minimizing risk."
Centinel Spine earned U.S. Food and Drug Administration (FDA) approval for 1-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova in July. The company claims to have broadest offering of cervical TDR implants in the world to address surgeon preference and patient anatomy.
Centinel Spine CEO Steve Murray stated, "This is a historic milestone for the company, and we appreciate the support from our surgeon partners. Total disc replacement is one of the fastest growing global segments in all of orthopedics, and we continue innovating in this area to advance patient care. With our recent regulatory achievements, we are now able to offer surgeons a unique range of options to match the disc to patient anatomy."
prodisc C Vivo has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices outside of the U.S., according to Centinel. The device has keel-less fixation and combines an anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation.
"This patient had severe left-sided neck pain radiating into the forearm and thumb and a left C5/6 disc herniation," Dr. Tinley told the press. "Having the intraoperative options of a convex dome with spikes (prodisc C Vivo) versus a flat endplate component with keel (prodisc C) gave me the modularity to maximize endplate contact and stability, thus decreasing bone removal, risk of heterotopic ossification, subsidence, or implant failure. Ultimately, this allows me to best restore motion while also minimizing risk."
Centinel Spine earned U.S. Food and Drug Administration (FDA) approval for 1-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova in July. The company claims to have broadest offering of cervical TDR implants in the world to address surgeon preference and patient anatomy.
Centinel Spine CEO Steve Murray stated, "This is a historic milestone for the company, and we appreciate the support from our surgeon partners. Total disc replacement is one of the fastest growing global segments in all of orthopedics, and we continue innovating in this area to advance patient care. With our recent regulatory achievements, we are now able to offer surgeons a unique range of options to match the disc to patient anatomy."
prodisc C Vivo has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices outside of the U.S., according to Centinel. The device has keel-less fixation and combines an anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation.